Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells
- 1 October 2006
- journal article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (20) , 7658-7666
- https://doi.org/10.1128/mcb.00363-06
Abstract
EVI1 is an aggressive nuclear oncoprotein deregulated by recurring chromosomal abnormalities in myelodysplastic syndrome (MDS). The expression of the corresponding gene is a very poor prognostic marker for MDS patients and is associated with severe defects of the erythroid lineage. We have recently shown that the constitutive expression of EVI1 in murine bone marrow results in a fatal disease with features characteristic of MDS, including anemia, dyserythropoiesis, and dysmegakaryopoiesis. These lineages are regulated by the DNA-binding transcription factor GATA1. EVI1 has two zinc finger domains containing seven motifs at the N terminus and three motifs at the C terminus. Supported by results of assays utilizing synthetic DNA promoters, it was earlier proposed that erythroid-lineage repression by EVI1 is based on the ability of this protein to compete with GATA1 for DNA-binding sites, resulting in repression of gene activation by GATA1. Here, however, we show that EVI1 is unable to bind to classic GATA1 sites. To understand the mechanism utilized by EVI1 to repress erythropoiesis, we used a combination of biochemical assays, mutation analyses, and in vitro bone marrow differentiation. The results indicate that EVI1 interacts directly with the GATA1 protein rather than the DNA sequence. We further show that this protein-protein interaction blocks efficient recognition or binding to DNA by GATA1. Point mutations that disrupt the geometry of two zinc fingers of EVI1 abolish the protein-protein interaction, leading to normal erythroid differentiation of normal murine bone marrow in vitro.Keywords
This publication has 36 references indexed in Scilit:
- Identification of Binding Sites of EVI1 in Mammalian CellsPublished by Elsevier ,2005
- PU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid DifferentiationMolecular and Cellular Biology, 2003
- SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivoOncogene, 2003
- The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cellsOncogene, 2002
- Interaction of EVI1 with cAMP-responsive Element-binding Protein-binding Protein (CBP) and p300/CBP-associated Factor (P/CAF) Results in Reversible Acetylation of EVI1 and in Co-localization in Nuclear SpecklesJournal of Biological Chemistry, 2001
- MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1Leukemia, 1999
- Key Residues Characteristic of GATA N-fingers Are Recognized By FOGPublished by Elsevier ,1998
- The Evil proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme developmentMechanisms of Development, 1997
- Functional analysis and in vivo footprinting implicate the erythroid transcription factor GATA-1 as a positive regulator of its own promoter.Genes & Development, 1991
- Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1.Genes & Development, 1990